Medtronic plc (MDT)

An “October Surprise” is usually a significant, late-breaking news event that generally occurs just before a November election and has the potential to influence its outcome.

Medtronic (MDT) closed the most recent trading day at $97.7, moving +2.33% from the previous trading session.

Some investors fear that President Donald Trump's aggressive tariffs will lead to economic troubles such as inflation. While things may or may not turn out that way, it's still a good idea to consider investing in companies that can help deal with the potential threat of rising prices.

GALWAY, Ireland , Sept. 29, 2025 /PRNewswire/ -- Medtronic plc (the "Company") (NYSE: MDT) announced today that its wholly-owned indirect subsidiary, Medtronic, Inc., has closed a registered public offering (the "Offering") of €750,000,000 principal amount of 2.950% senior notes due 2030 and €750,000,000 principal amount of 4.200% senior notes due 2045 (collectively, the "Notes").

In the closing of the recent trading day, Medtronic (MDT) stood at $94.3, denoting a -1.5% move from the preceding trading day.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

New product leverages MDT investment team's three decades of experience and skill PITTSBURGH , Sept. 25, 2025 /PRNewswire/ -- Federated Hermes, Inc. (NYSE: FHI), a global leader in active investing, today introduced Federated Hermes MDT Market Neutral ETF (NYSE: MKTN).

Medtronic (MDT) is undervalued, with strong organic growth and an 11% upside to a $105 target price, supporting a Buy rating. MDT's innovation pipeline, portfolio transformation, and spin-off of the diabetes business are set to accelerate revenue and profit growth in FY26. Shares trade at a significant discount to peers despite robust margins, strong cash flow, and a 3.1% dividend yield, enhancing total return potential.

Technological advances are a key driver in the healthcare sector. One of the areas in which massive change has been taking place is surgery, with surgical robots helping to improve patient outcomes in a big way.

Medtronic plc (NYSE:MDT ) Bank of America Global Healthcare Conference 2025 September 24, 2025 9:10 AM EDT Company Participants Thierry Pieton - Executive VP & CFO Presentation Unknown Analyst We're glad to have the Medtronic CFO, Thierry Pieton, here with us. So welcome.

MDT gains FDA approval for its Altaviva device, a minimally invasive bladder control therapy with long-lasting benefits.

Medtronic (MDT -0.68%) is out of favor today, noting it has a historically high dividend yield of around 3%. The company is working on improving its business performance, however, and stronger results are likely on tap.

The Implantable Tibial Neuromodulation (ITNM) device will expand treatment options for the 16 million people living with urinary urges and involuntary leaks GALWAY, Ireland , Sept. 19, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced today that it has received U.S. Food and Drug Administration (FDA) approval for the Altaviva™ device.

Medtronic (MDT) reported earnings 30 days ago. What's next for the stock?

Medtronic remains a Buy for long-term investors, offering steady growth, durable income, and an attractive valuation below historical averages. MDT delivered solid fiscal Q1 2026 results, with 8.4% revenue growth and standout performance in Cardiac Ablation and Diabetes segments. The upcoming diabetes segment spinoff is expected to improve operating margins and reinforce MDT's growth trajectory.

The list of Dividend Kings -- the very few U.S.-traded stocks that have enacted dividend raises at least once annually for a minimum of 50 years in a row -- is extremely short. That's why it's quite an event when a new stock joins this very limited and exclusive club.